Which endpoint to choose ? (in phase II sarcoma clinical trials) George D. Demetri, MD Dana-Farber / Harvard Cancer Center, Boston Mass. USA for Robert.
Which endpoint to choose ? (in phase II sarcoma clinical trials)
